These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 32239325)
21. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma. Villasboas JC; Ansell S Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012 [TBL] [Abstract][Full Text] [Related]
22. Nivolumab in the Treatment of Hodgkin Lymphoma. Ansell SM Clin Cancer Res; 2017 Apr; 23(7):1623-1626. PubMed ID: 27881581 [TBL] [Abstract][Full Text] [Related]
23. Cancer Immunotherapy and the Immune Response in Hodgkin Lymphoma. Renner C; Stenner F Front Oncol; 2018; 8():193. PubMed ID: 29915720 [TBL] [Abstract][Full Text] [Related]
24. Hodgkin Lymphoma: A disease shaped by the tumor micro- and macroenvironment. Masel R; Roche ME; Martinez-Outschoorn U Best Pract Res Clin Haematol; 2023 Dec; 36(4):101514. PubMed ID: 38092473 [TBL] [Abstract][Full Text] [Related]
25. Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization. Hartmann S; Martin-Subero JI; Gesk S; Hüsken J; Giefing M; Nagel I; Riemke J; Chott A; Klapper W; Parrens M; Merlio JP; Küppers R; Bräuninger A; Siebert R; Hansmann ML Haematologica; 2008 Sep; 93(9):1318-26. PubMed ID: 18641027 [TBL] [Abstract][Full Text] [Related]
26. Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma. Aoki T; Chong LC; Takata K; Milne K; Marshall A; Chavez EA; Miyata-Takata T; Ben-Neriah S; Unrau D; Telenius A; Boyle M; Weng AP; Savage KJ; Scott DW; Farinha P; Shah SP; Nelson BH; Steidl C Proc Natl Acad Sci U S A; 2021 Oct; 118(41):. PubMed ID: 34615710 [TBL] [Abstract][Full Text] [Related]
27. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Green MR; Rodig S; Juszczynski P; Ouyang J; Sinha P; O'Donnell E; Neuberg D; Shipp MA Clin Cancer Res; 2012 Mar; 18(6):1611-8. PubMed ID: 22271878 [TBL] [Abstract][Full Text] [Related]
28. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial. Gerhard-Hartmann E; Goergen H; Bröckelmann PJ; Mottok A; Steinmüller T; Grund J; Zamò A; Ben-Neriah S; Sasse S; Borchmann S; Fuchs M; Borchmann P; Reinke S; Engert A; Veldman J; Diepstra A; Klapper W; Rosenwald A Br J Haematol; 2022 Jan; 196(1):116-126. PubMed ID: 34520052 [TBL] [Abstract][Full Text] [Related]
29. Checkpoint inhibition therapy as possible frontline therapy for Hodgkin lymphoma. Khurana A; Armand P; Ansell SM Leuk Lymphoma; 2020 May; 61(5):1063-1074. PubMed ID: 31914840 [TBL] [Abstract][Full Text] [Related]
30. The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative. Patel SS; Weirather JL; Lipschitz M; Lako A; Chen PH; Griffin GK; Armand P; Shipp MA; Rodig SJ Blood; 2019 Dec; 134(23):2059-2069. PubMed ID: 31697809 [TBL] [Abstract][Full Text] [Related]
31. Lymphomagenesis in Hodgkin lymphoma. Matsuki E; Younes A Semin Cancer Biol; 2015 Oct; 34():14-21. PubMed ID: 25725205 [TBL] [Abstract][Full Text] [Related]
32. Digital spatial profiling of CD4 Takeuchi M; Miyoshi H; Semba Y; Yamada K; Nakashima K; Sato K; Furuta T; Moritsubo M; Ogura Y; Tanaka K; Imamoto T; Arakawa F; Kohno K; Ohshima K Virchows Arch; 2023 Aug; 483(2):255-260. PubMed ID: 37270432 [TBL] [Abstract][Full Text] [Related]
33. Diagnostic Utility of STAT6 and pSTAT6 Immunohistochemistry for Distinguishing Classic Hodgkin Lymphoma and Peripheral T-Cell Lymphoma With Hodgkin and Reed-Sternberg-like Cells. Satou A; Takahara T; Yamashita D; Seki M; Kato S; Tanioka F; Tsuyuki T; Wada E; Sakurai K; Karube K; Tsuzuki T; Nakamura S Am J Surg Pathol; 2023 Aug; 47(8):897-906. PubMed ID: 37248961 [TBL] [Abstract][Full Text] [Related]
34. 9p24.1 Genetic Alteration and PD-L1 Expression Are Characteristic of De Novo and Methotrexate-associated Epstein-Barr Virus-positive Hodgkin Lymphoma, But Not Methotrexate-associated Hodgkin-like Lesions. Shiraiwa S; Kikuti YY; Carreras J; Kondo Y; Ohmachi K; Ogawa Y; Kawada H; Sato S; Gion Y; Sato Y; Nakamura N; Ando K Am J Surg Pathol; 2022 Aug; 46(8):1017-1024. PubMed ID: 35848760 [TBL] [Abstract][Full Text] [Related]
35. Complex Immune Evasion Strategies in Classical Hodgkin Lymphoma. Wein F; Weniger MA; Höing B; Arnolds J; Hüttmann A; Hansmann ML; Hartmann S; Küppers R Cancer Immunol Res; 2017 Dec; 5(12):1122-1132. PubMed ID: 29070649 [TBL] [Abstract][Full Text] [Related]
36. A malignant lymphoma with histological features and immunophenotypic profile intermediate between EBV-positive diffuse large B-cell lymphoma and EBV-positive classical Hodgkin lymphoma in a 67-year-old female: a "gray zone" lymphoma associated with Epstein-Barr virus in the elderly. Wang E; Papavassiliou P; Sebastian S Pathol Res Pract; 2012 Jun; 208(6):363-7. PubMed ID: 22572037 [TBL] [Abstract][Full Text] [Related]